

**Prevalence of Thyroid Dysfunction in Chronic  
Hepatitis C Patients Treated with and without  
Interferon and Ribavirin**

**Essay**

Submitted for partial fulfillment of master degree In  
**Internal Medicine**

By

**Mostafa Abdul Mogheeth Mohamed Allam**  
M.B.B.ch

**Under Supervision of**

**Prof.Dr.Mohamed Ali Marei Makhoul**

Professor of Internal Medicine  
Faculty of Medicine - Ain Shams University

**Prof.Dr.Mansor Nasef Mohamed**

Professor of Internal Medicine  
Faculty of Medicine - Ain Shams University

**Dr.Amir Helmy Samy**

Assistant Professor of Internal Medicine  
Faculty of Medicine - Ain Shams University

**Faculty of Medicine  
Ain Shams University  
2014**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَقُلْ اَعْمَلُوا فَسَيَرَى اللَّهُ عَمَلَكُمْ  
وَرَسُولُهُ وَالْمُؤْمِنُونَ

صدق الله العظيم

سورة التوبة آية (١٠٥)



First, thanks are all due to **Allah** for Blessing this work until it has reached its end, as a part of his generous help throughout our life.

It is a great honor for me to take this opportunity to express my deepest gratitude to **Prof. Dr. Mohamed Ali Marei Makhlouf**, Professor of internal medicine, Faculty of Medicine, Ain Shams University for selection of this subject, expert guidance, valuable advice and generous encouragement and support offered to me throughout this work.

I would like to express my greatest appreciation and thanks to **Prof. Dr. Mansor Nasef Mohamed**, Professor of internal medicine, Faculty of Medicine, Ain Shams University for valuable support throughout this work and for her kind supervision and helpful guidance throughout this work.

It is a pleasure to express my greatest appreciation and thanks to **Dr. Amir Helmy Samy**, Assistant Professor of internal medicine, Faculty of Medicine, Ain Shams University for her kind supervision and helpful guidance throughout this work.

I am extremely sincere to **my family** who stood beside me throughout this work giving me their support.



**Mostafa Allam**

# List of Contents

Page No.

Acknowledgments .....	--
List of Abbreviations .....	i
List of Figures .....	vi
List of Tables .....	viii
<b>Introduction</b> .....	1
<b>Aim of the work</b> .....	3

## **Chapter 1: Hepatitis C Virus**

• Introduction.....	4
• Viral Structure.....	4
• Epidemiology.....	5
• HCV Transmission.....	6
• Acute Hepatitis.....	8
• Chronic Hepatitis.....	10
• Natural History.....	10
• HCV and disease progression.....	10
• Factor affecting HCV progression.....	11
• Cirrhosis and Hepatic Decompensation.....	12
• Hepatitis C virus and Hepatocellular carcinoma .....	13
• Extrahepatic manifestation of HCV.....	13
A. Immune Manifestations of HCV.....	15
1. Cryoglobulinemia.....	15
2. Non-Hodgkin's Lymphoma.....	17
3. Renal Disorders .....	18
4. HCV-Related Arthritis .....	20
B. HCV-Related Endocrinological Disorders.....	21
1. Thyroid Disorders and HCV.....	21
2. Insulin Resistance and Type 2 Diabetes .....	23
• Future Perspective in the Treatment of Extrahepatic Manifestations of HCV Potential Role of DAAs.....	24
• Diagnosis of chronic hepatitis C .....	24
• Treatment of Hepatitis C virus .....	25

# List of Contents (Cont.)

	Page No.
• Indications for treatment .....	25
• Pretreatment Assessments .....	26
• Treatment .....	30
• Treatment Options .....	33
• EASL Recommendations on Treatment of Hepatitis C 2014 .....	35
• Current treatment recommendations for chronic hepatitis C infection (American Association for the Study of Liver Diseases [AASLD] and the Infectious Disease Society of America [ISDA] .....	45
• Adverse effects of treatment .....	47
<b>Chapter 2 : Thyroid Gland</b>	
• Embryology of Thyroid gland .....	50
• Thyroid Anatomy .....	51
• Blood Supply .....	51
• Nerves .....	52
• Lymphatic System .....	52
• Thyroid Histology .....	53
• Physiology of the Thyroid gland .....	54
• Evaluation of Patients with Thyroid Disease .....	56
A. Tests of thyroid function .....	56
B. Thyroid Imaging.....	59
• Thyroid Disorders.....	62
1. Goiter.....	62
2. Hyperthyroidism.....	67
3. Hypothyroidism.....	73
4. Thyroiditis.....	81
5. Thyroid cancer.....	88

# List of Contents (Cont.)

Page No.

## Chapter 3: Chronic Hepatitis C and Thyroid Dysfunction

- Normal metabolic interplay between the liver and thyroid.....91
  - I. Thyroid Dysfunction in Chronic Hepatitis C Patients untreated with Pegylated interferon and Ribavirin.....91
- Antithyroid Autoantibodies in Chronic Hepatitis C Patients.....92
- Hypothyroidism.....94
- Papillary thyroidcarcinoma.....100
- Prevalence of Thyroid dysfunction in chronic hepatitis C patient untreated with Pegylated interferon and Ribavirin.....102
  - II. Thyroid Dysfunction in Chronic Hepatitis C Patients treated with Pegylated Interferon and Ribavirin.....104
- Effects of interferon on thyroid function .....106
- Effects of ribavirin on thyroid function .....107
- Factors predisposing to development of thyroid Functions disorders.....108
- Clinical spectrum of interferon induced thyroid disease (IITD) .....109
  - Manifestations of IITD.....110
    - A. Autoimmune interferon-induced thyroiditis (IIT).....110
      - 1. Hashimoto's thyroiditis.....110
      - 2. Grave's disease.....111
    - B. Non-autoimmune interferon-induced thyroiditis (IIT).....114
      - 1. Destructive thyroiditis .....114
      - 2. Non-autoimmune hypothyroidism.....114
  - Pathogenesis of IITD.....117

# List of Contents (Cont.)

	Page No.
○ Association of IITD with interferon and ribavirin treatment regimens.....	121
○ Association of IITD with Response to interferon and ribavirin treatment .....	122
○ Clinical Features, Diagnosis and Treatment of IITD.....	123
○ Outcome of IITD.....	124
▪ Principles of monitoring and early diagnosis of thyroid dysfunction during IFNa and Ribavirin treatment.....	126
▪ Prevalence of thyroid dysfunction during the treatment of patients with chronic hepatitis C with pegylated interferon and ribavirin.....	126
▪ Treatment of thyroid function disorders.....	128
<b>Summary .....</b>	<b>131</b>
<b>Conclusion.....</b>	<b>138</b>
<b>References.....</b>	<b>139</b>
<b>Arabic summary</b>	

## List of Abbreviations

<b>123I</b>	: Iodine 123
<b>131I</b>	: Iodine 131
<b>AASLD</b>	: American association for study of liver disease
<b>AIDS</b>	: Acquired immune deficiency syndrome
<b>AITD</b>	: Autoimmune thyroid disorder
<b>ALT</b>	: Alanin aminotransferase
<b>AMA</b>	: Anti-microsomal antibody
<b>ANA</b>	: Antinuclear antibody
<b>ASMA</b>	: Anti-smooth muscle antibody
<b>AST</b>	: Aspartate transaminase
<b>ATD</b>	: Antithyroid drug
<b>BOC</b>	: Boceprevir
<b>C</b>	: Complement
<b>CD</b>	: Cluster differentiation
<b>CHC</b>	: Chronic hepatitis C
<b>CIA</b>	: Chemoluminescence immunoassay
<b>COX-2</b>	: Cyclooxygenase-2
<b>CT</b>	: Computed tomography
<b>CTLA</b>	: Cytotoxic T-lymphocyte associated
<b>DAA</b>	: Direct acting antiviral



<b>E2</b>	: Envelope 2
<b>EASL</b>	: European association for study of liver disease
<b>ECG</b>	: Electrocardiography
<b>EHMs</b>	: Extrahepatic manifestations
<b>EIA</b>	: Enzyme immunoassay
<b>ESR</b>	: Erythrocyte sedimentation rate
<b>FDA</b>	: Food and drug administration
<b>FDG</b>	: Flurodeoxyglucose
<b>FNAB</b>	: Fine needle aspiration biopsy
<b>FTI</b>	: Free thyroid index
<b>GD</b>	: Grave's disease
<b>HAV</b>	: Hepatitis A virus
<b>HBcAg</b>	: Hepatitis B core antigen
<b>HBsAg</b>	: Hepatitis B surface antigen
<b>HCC</b>	: Hepatocellular carcinoma
<b>HCV</b>	: Hepatitis C virus
<b>HIV</b>	: Humman immunodeficiency virus
<b>HLA</b>	: Human leukocyte antigen
<b>IDU</b>	: Intravenous drug use
<b>IgA</b>	: Immunoglobulin A
<b>IgM</b>	: Immunoglobulin M
<b>IITD</b>	: Interferone induced thyroid disease

<b>iNOS</b>	: Inducible nitric oxide synthetase
<b>IR</b>	: Insulin resistance
<b>ISDA</b>	: Infectious diseases society of America
<b>IV</b>	: Intravenous
<b>JAK STAT</b>	: Janus kinase signal transducer and activator of transcription
<b>KDIGO</b>	: Kidney disease improving global outcome
<b>LPDs</b>	: Lymphoproliferative disorders
<b>LT</b>	: Levothyroxine
<b>MALT</b>	: Mucosa associated lymphoid tissue
<b>MC</b>	: Mixed cryoglobulinemia
<b>MHC</b>	: Major histocompatibility
<b>MRI</b>	: Magnetic resonance imaging
<b>mRNA</b>	: messenger ribonucleic acid
<b>NHANES</b>	: National Health and Nutrition Examination Survey
<b>NHL</b>	: Non-Hodgkin's lymphoma
<b>NK</b>	: Natural killer
<b>NS</b>	: Non-structural
<b>NSAIDs</b>	: Non steroidal anti-inflammatory drugs
<b>PCR</b>	: Polymerase chain reaction
<b>PEG-INF</b>	: Pegylated interferone
<b>PET</b>	: Position emission tomography
<b>PI</b>	: Protease inhibitors

<b>PTPN</b>	: Protein tyrosine phosphatase non receptor
<b>RA</b>	: Rheumatoid arthritis
<b>RAI</b>	: Radioactive iodine
<b>RBV</b>	: Ribavirin
<b>RGT</b>	: Response guided therapy
<b>RLN</b>	: Recurrent laryngeal nerve
<b>RNA</b>	: Ribonucleic acid
<b>SAT</b>	: Subacute thyroiditis
<b>SLVL</b>	: Splenic lymphoma with villous lymphocyte
<b>SOCS3</b>	: Suppressor of cytokine signaling 3
<b>STAT-C</b>	: Signal transducer and activator of transcription C
<b>SVR</b>	: Sustained virologic response
<b>T2DM</b>	: Type 2 diabetes mellitus
<b>T3</b>	: Triiodothyronine
<b>T4</b>	: Thyroxine
<b>TAB</b>	: Thyroid antibody
<b>TBG</b>	: Thyroid binding globulin
<b>TBPA</b>	: Thyroid binding pre-albumin
<b>TD</b>	: Thyroid dysfunction
<b>TG</b>	: Thyroid globulin
<b>TH</b>	: T-helper
<b>TPO</b>	: Thyroid peroxidase

<b>TRAb</b>	: Thyroid stimulating hormone receptor antibody
<b>TRH</b>	: Thyroid releasing hormone
<b>TSH</b>	: Thyroid stimulating hormone
<b>TSI</b>	: Thyroid stimulating immunoglobulin
<b>TVR</b>	: Telaprevir
<b>UK</b>	: United Kingdom
<b>VEGF</b>	: Vascular epidermal growth factor
<b>WHO</b>	: World health organization

# List of Figures

No.		Page
<b>Chapter 1</b>		
<b>1</b>	(a) Viral structure and genome demonstrating potential therapeutic targets. (b) Reproduced with permission from HCV	<b>5</b>
<b>2</b>	Summary of natural history of hepatitis C infection	<b>11</b>
<b>Chapter 2</b>		
<b>1</b>	Anatomy of the thyroid gland and surrounding structures, viewed anteriorly ( <b>A</b> ) and in cross-section ( <b>B</b> )	<b>51</b>
<b>2</b>	<b>A</b> and <b>B</b> . Lymph nodes in the neck can be divided into six regions. Upper mediastinal nodes constitute level VII.	<b>53</b>
<b>3</b>	Normal thyroid histology—follicular cells surround colloid	<b>54</b>
<b>4</b>	Synthesis and metabolism of the thyroid hormones	<b>55</b>
<b>5</b>	Radioactive iodine scan of the thyroid, with the arrow showing an area of decreased uptake, a cold nodule	<b>60</b>
<b>6</b>	Thyroid ultrasound showing a lymph node (arrow) along the carotid artery	<b>61</b>

<b>7</b>	Thyroid nuclear scan of a patient with a euthyroid goiter showing different projections	<b>62</b>
<b>8</b>	Symptoms and signs of hypothyroidism	<b>79</b>
<b>Chapter 3</b>		
<b>1</b>	Interpretation of hypothyroid function test results	<b>97</b>
<b>2</b>	Guidelines for the early recognition of thyroid dysfunction	<b>106</b>

# List of Tables

No.		Page
<b>Chapter 1</b>		
<b>1</b>	Laboratory Criteria for Diagnosis of Acute Hepatitis C Confirmation of acute hepatitis C is confirmed by all of the following	<b>9</b>
<b>2</b>	Classification of extrahepatic manifestations of HCV infection	<b>14</b>
<b>3</b>	pretreatment assessments in chronic hepatitis C patients	<b>27</b>
<b>4</b>	lists virologic responses to treatment of HCV infection	<b>31</b>
<b>5</b>	Contraindications to Treatment for Chronic HCV Infection	<b>32-33</b>
<b>6</b>	lists factors that predict sustained virologic response	<b>34-35</b>
<b>7</b>	Summary of Recommendations for Patients Who are Initiating Therapy for HCV Infection.	<b>46</b>
<b>8</b>	Adverse Effects of Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus Infection	<b>48-49</b>